10-Q: Elutia Inc. Reports Q3 2026 Results, Faces Net Loss

Elutia Inc. filed its Q3 2026 Form 10-Q, detailing continued net losses and increased R&D expenses, alongside revenue growth and the impact of recent divestitures.

Summary

• Elutia Inc. reported net sales of $1.1 million for the three months ended September 30, 2026, an increase from $0.9 million in the same period last year.
• The company incurred a net loss of $1.3 million for the three months ended September 30, 2026, compared to a net loss of $3.9 million for the same period in 2025.
• Operating expenses increased by 19.3% to $7.6 million for the three months ended September 30, 2026, driven by higher R&D spending.
• Research and development expenses significantly increased by 173.6% to $3.0 million, reflecting investment in NXT-41 and NXT-41x.
• The company completed the sale of its SimpliDerm Business on August 17, 2026, and its CIED Business on October 1, 2025.
• As of September 30, 2026, Elutia had $29.1 million in cash and cash equivalents.
• The company is facing ongoing litigation related to FiberCel and VBM products, with significant legal costs incurred.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the continued net losses, significant operating expenses, and ongoing litigation, despite some revenue growth and strategic divestitures.

Positives

• Net sales increased by 20.4% to $1.1 million for the three months ended September 30, 2026, compared to $0.9 million in the prior year period.
• Gross profit increased by 41.0% to $0.7 million for the three months ended September 30, 2026, from $0.5 million in the prior year period.
• Gross margin improved to 61.7% from 52.8% for the three months ended September 30, 2026, compared to the same period in 2025.
• The company received $7.5 million in net cash from investing activities, primarily from the sale of its SimpliDerm Business.
• The company secured a new $15 million senior secured term loan facility from Avenue Venture Opportunities Fund II, L.P. and Avenue Growth Lending Fund III, L.P.

Negatives

• The company reported a net loss of $1.3 million for the three months ended September 30, 2026, and a net loss of $16.4 million for the nine months ended September 30, 2026.
• Total operating expenses increased by 19.3% to $7.6 million for the three months ended September 30, 2026.
• Research and development expenses increased significantly by 173.6% to $3.0 million for the three months ended September 30, 2026.
• Litigation costs, net, decreased significantly but remain a factor, with $0.1 million in the three months ended September 30, 2026, compared to $0.9 million in the prior year.
• The company has an accumulated deficit of $192.6 million as of September 30, 2026.
• The company received a notice from Nasdaq regarding its stock's closing bid price being below $1.00, with a 180-day compliance period until February 2, 2027.

Risks

• The company may be unable to draw the Second Tranche Term Loan of $5 million, which is subject to FDA clearance of NXT-41x and liquidity conditions.
• The company faces ongoing litigation related to FiberCel and VBM products, with potential for material adverse financial consequences.
• The company's ability to continue as a going concern is dependent on its ability to generate cash flows from product sales and/or raise additional capital.
• The company's loan agreement with Avenue contains restrictive covenants that may limit its flexibility and could lead to acceleration of indebtedness and foreclosure on assets.
• The exercise of outstanding warrants and the conversion option could dilute existing stockholders and make future financings more difficult.
• Changes in the fair value of warrant and derivative liabilities can cause significant volatility in reported results.
• The company relies on a limited number of third-party suppliers, including Cook as the sole supplier for its remaining Cardiovascular products.
• The company may not be able to regain compliance with Nasdaq's minimum bid price requirement.

Future Outlook

The company expects to incur operating losses and negative cash flows from operations for the foreseeable future as it advances the development and commercialization of NXT-41 and NXT-41x. Future viability depends on generating cash from sales or raising additional capital. The company may seek equity or debt financing, asset sales, or other transactions, but success is not guaranteed.

Management Comments

• StockSavvy.ai notes that management's focus is on advancing the drug-eluting biomatrix (DEB) platform, building on biologic matrix and local drug delivery capabilities.
• Management believes the foundational technology can be applied to reconstructive and soft tissue repair markets with significant unmet medical needs.
• The company is aggressively pursuing the development of NXT-41 and NXT-41x, its next-generation biologic matrices.

Industry Context

StockSavvy.ai observes that Elutia operates in the medical device sector, specifically focusing on drug-eluting biomatrix products for surgical reconstruction. The company highlights the substantial market opportunity in reconstructive and soft tissue repair, estimated at $1.5 billion in the U.S., where complication rates remain high despite the prevalence of biologic matrices.

Comparison to Industry Standards

• The company's focus on drug-eluting biomatrix products aligns with trends in advanced wound care and surgical implant technologies, aiming to reduce complications like infection and inflammation.
• The reported R&D spending increase reflects a common strategy in the medical device industry to invest heavily in next-generation product development to gain a competitive edge.
• The company's struggle with Nasdaq's minimum bid price requirement is a challenge faced by some smaller, growth-stage companies in the biotech and medical device sectors, often necessitating strategic financial maneuvers or stock consolidation.

Legal Proceedings

• FiberCel Litigation: 3 active lawsuits/claims, 106 settled, 1 statute of limitations expired. Allegations involve tuberculosis exposure and complications.
• Viable Bone Matrix (VBM) Litigation: 7 active lawsuits, 19 settled, 1 dismissed, 9 potential claims with expired statutes of limitations. Allegations involve tuberculosis exposure and complications.
• Medtronic Litigation: Settled on July 20, 2026, with Elutia agreeing to pay $1.78 million in installments or a lump sum of $1.513 million.
• Tiger Litigation: Settled on June 24, 2026, with claims dismissed with prejudice and no material payments exchanged.
• Supplier Litigation: Lawsuit filed by a former supplier in October 2024; trial set for May 2027. Company is defending the matter.

Stakeholder Impact

• Shareholders: Potential dilution from warrant exercises and conversion options; risk of Nasdaq delisting if minimum bid price is not met.
• Lenders (Avenue): Secured by substantially all company assets; potential for acceleration of debt and foreclosure if covenants are breached.
• Creditors: Continued losses and reliance on future financing could impact the company's ability to meet its obligations.
• Employees: Continued investment in R&D and potential for future growth may impact job security and opportunities.

Next Steps

• Advance the development and commercialization of NXT-41 and NXT-41x.
• Regain compliance with Nasdaq's minimum bid price requirement by February 2, 2027.
• Potentially draw the Second Tranche Term Loan between May 1, 2027, and September 30, 2027, subject to conditions.
• Continue to manage ongoing litigation related to FiberCel and VBM products.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' due to the mixed financial results. While there is revenue growth and strategic divestitures have occurred, the company continues to face significant net losses, high operating expenses, ongoing litigation, and regulatory concerns (Nasdaq minimum bid price). The new loan provides some liquidity, but the path to profitability remains uncertain and dependent on successful product development and future financing.

Keywords

biomatrix products, drug-eluting, surgical reconstruction, NXT-41, NXT-41x, Form 10-Q, litigation, divestiture